According to a recent report, 3,458 deaths occurred and more than 14,300 people in India reported side effects in clinical trials between 2005 and 2013, but in only 89 cases was any compensation given.  How can we make ethical research in India a priority? Experts argue that the solution requires a pharmacovigilance framework where regulatory bodies acquire clinical data independent of company sources.